Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$2.60 – $2.96
Volume40,824
Market cap$11M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for PBM.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for PBM.
Recent news
Company coverage with links to the original publishers.
Psyence Biomedical Ltd. (Nasdaq: PBM) announced that PsyLabs has exercised its put option rights, resulting in a Share-for-Share Exchange where Psyence will issue 1,146,159 common shares valued at $5 million to acquire 2,900 PsyLabs shares. Following the transaction, PsyLabs will own approximately 49.98% of Psyence BioMed. The deal is expected to close on February 25, 2026, and aims to strengthen supply chain security for pharmaceutical-grade psychedelic compounds as the company advances its clinical programs.
Psyence BioMed's board has ratified a put option agreement with PsyLabs, a leading pharmaceutical-grade psychedelic manufacturer. The agreement grants PsyLabs the right to require Psyence to make further equity investments while securing reliable supply of pharmaceutical-grade psychedelics for clinical and commercial programs. The structure preserves Psyence's near-term financial flexibility while advancing its development pathway.
Psyence Biomedical Ltd. (Nasdaq: PBM) announced that its 1-for-6.25 reverse stock split will become effective on February 2, 2026, after being delayed from its original January 20 date. The consolidation will reduce outstanding shares from 6,388,604 to 1,022,177. The company's shares will continue trading under the symbol 'PBM' with a new CUSIP number.
Psyence Biomedical Ltd. (Nasdaq: PBM) announced the adjournment of its annual and special shareholder meeting originally scheduled for January 22, 2026, to February 12, 2026, due to failure to achieve the requisite quorum. The company is working with proxy agents to ensure sufficient shareholder participation at the rescheduled meeting.
Psyence BioMed advanced its Phase IIb clinical trial for psilocybin-assisted psychotherapy in palliative care, secured nature-derived psilocybin and ibogaine supply, and positioned itself as a leader in longevity science research.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.